Skip to main content
Porton Pharma Solutions Ltd. logo

Porton Pharma Solutions Ltd. — Investor Relations & Filings

Ticker · 300363 ISIN · CNE100001S57 LEI · 300300IQTJFHA0YRXE68 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,163 across all filing types
Latest filing 2026-04-03 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300363

About Porton Pharma Solutions Ltd.

https://www.porton.cn

Porton Pharma Solutions Ltd. is a global contract development and manufacturing organization (CDMO) providing end-to-end solutions for the pharmaceutical and biotechnology sectors. The company specializes in the development and manufacturing of small molecule APIs, intermediates, and drug products, while expanding its capabilities into biologics and cell and gene therapies. Its service portfolio encompasses process research and development, analytical services, pilot-scale production, and large-scale commercial manufacturing. Porton operates a network of R&D centers and manufacturing facilities designed to meet international regulatory standards, including those of the FDA and EMA. By leveraging an integrated technology platform, the company supports clients throughout the entire drug lifecycle, from preclinical development to commercialization, focusing on operational excellence and supply chain security.

Recent filings

Filing Released Lang Actions
对外投资管理制度（2026年4月）
Governance Information Classification · 95% confidence The document is titled '重庆博腾制药科技股份有限公司 对外投资管理制度' which translates to 'Chongqing Boteng Pharmaceutical Technology Co., Ltd. External Investment Management System'. It is a detailed internal policy document outlining the company's procedures, principles, approval authorities, organizational management, decision-making, financial management, auditing, and disclosure obligations related to external investments. The document includes references to company law, securities law, and stock exchange listing rules, but it is not a financial report, earnings release, or announcement. It is a governance-related document detailing internal rules and procedures for managing external investments. It does not contain financial statements or results, nor is it an announcement or notice. Therefore, the most appropriate classification is Governance Information (CGR). The document length (7622 characters) supports it being a full policy document rather than a brief announcement.
2026-04-03 Chinese
关于调整投资基金认购份额的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Chongqing Boteng Pharmaceutical Technology Co., Ltd. regarding an adjustment in the subscription amount of an investment fund. It details the board meeting decisions, changes in the company's committed capital to the fund, and the impact on the company. The document is a formal announcement about a capital investment adjustment, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis but rather informs shareholders and the public about a change in investment commitment. This fits the category of Capital/Financing Update (CAP). The document length is 2315 characters, which is typical for an announcement rather than a full report.
2026-04-03 Chinese
关于2026年度开展外汇衍生品交易业务的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Chongqing Boteng Pharmaceutical Technology Co., Ltd. regarding the company's plan to engage in foreign exchange derivative trading business for the year 2026. It details the investment purpose, amount, types of derivatives, risk analysis, risk control measures, accounting treatment, and impact on the company. The document references a board meeting resolution approving this business activity and includes risk disclosures and regulatory compliance statements. It does not contain financial statements or quarterly/yearly financial results, nor is it a transcript, audit report, or management report. It is a regulatory announcement about a capital/financing related activity (foreign exchange derivatives trading authorization and risk disclosure). Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is 3049 characters, which is consistent with an announcement rather than a full report.
2026-04-03 Chinese
关于召开2025年度股东会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2025 Annual General Meeting (AGM) of Chongqing Porton Pharmaceutical Technology Co., Ltd. It includes information about the meeting date, voting procedures, proposals to be discussed, registration details, and proxy forms. There is no financial data or report content, only the announcement and procedural details for the AGM. The document length is 4091 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2026-04-03 Chinese
2025年度募集资金年度存放、管理与使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "募集资金年度存放、管理与使用情况鉴证报告" which translates to "Annual Verification Report on the Storage, Management, and Use of Raised Funds." It includes a verification report by a registered accounting firm, references to regulatory rules on raised funds management, detailed financial data on raised funds usage, and compliance with regulatory requirements. The document is about the annual management and use of capital raised by the company, with detailed financial tables and auditor's verification. This type of document is a standalone audit or verification report related to the use of capital raised, not a full annual report or interim report. It is not an announcement or a brief summary but a detailed verification report. Therefore, it fits best under the category Audit Report / Information (AR).
2026-04-03 Chinese
董事会审计委员会对会计师事务所2025年度履职情况评估及履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from the Board Audit Committee evaluating the performance of the accounting firm Tianjian for the fiscal year 2025. It discusses the audit firm's qualifications, audit procedures, independence, and the audit report issued for the company's 2025 annual financial statements. The document includes references to the audit report, audit plan communications, and supervisory activities by the audit committee. It is not the full annual report itself but a specific report on the audit firm's performance and the audit committee's oversight. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and related supervisory information, excluding the full annual report. The document length is 3062 characters, which is sufficient for a detailed report but not a brief announcement. Therefore, the classification is AR with high confidence.
2026-04-03 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.